The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:

##STR00001##

wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently —CR.sub.2═ or —N═, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, —S(═O).sub.2—NH—R.sub.8, R.sub.8 is, for example, a C1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:

##STR00001##

wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently —CR.sub.2═ or —N═, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, —S(═O).sub.2—NH—R.sub.8, R.sub.8 is, for example, a C1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).

The present subject matter relates to a process for separating compound (I) from a mixture comprising compound (I). The present subject matter also relates to a process for separating compound (I) from a mixture comprising compound (I) and compound (II).